PMID- 35627822
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220716
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 19
IP  - 10
DP  - 2022 May 22
TI  - Metabolic-Syndrome-Related Comorbidities in Narcolepsy Spectrum Disorders: A 
      Preliminary Cross-Sectional Study in Japan.
LID - 10.3390/ijerph19106285 [doi]
LID - 6285
AB  - Narcolepsy types 1 (NT1) and 2 (NT2) and idiopathic hypersomnia (IH) are thought 
      to be a disease continuum known as narcolepsy spectrum disorders (NSDs). This 
      study aimed to assess the prevalence of and factors associated with 
      metabolic-syndrome-related disorders (MRDs) among patients with NSD. Japanese 
      patients with NSD (NT1, n = 94; NT2, n = 83; and IH, n = 57) aged >/=35 years were 
      enrolled in this cross-sectional study. MRD was defined as having at least one of 
      the following conditions: hypertension, diabetes, or dyslipidemia. Demographic 
      variables and MRD incidence were compared among patients in the respective NSD 
      categories. Multivariate logistic regression analysis was used to investigate the 
      factors associated with MRDs. Patients with NT1 had a higher body mass index 
      (BMI) and incidence of MRD than that had by those with NT2 or IH. Age, BMI, and 
      the presence of OSA were significantly associated with the incidence of MRD in 
      NSDs. Age and BMI in NT1, BMI and human leukocyte antigen (HLA)-DQB1*06:02 
      positivity in NT2, and only age in IH were factors associated with the incidence 
      of MRD. Obesity should be carefully monitored in narcolepsy; however, NT2 with 
      HLA-DQB1*06:02 positive should be followed up for the development of MRD even 
      without obesity.
FAU - Futenma, Kunihiro
AU  - Futenma K
AUID- ORCID: 0000-0002-5583-6134
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, 207, Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, Japan.
AD  - Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, 
      Shinjuku-ku, Tokyo 151-0053, Japan.
FAU - Takaesu, Yoshikazu
AU  - Takaesu Y
AD  - Department of Neuropsychiatry, Graduate School of Medicine, University of the 
      Ryukyus, 207, Uehara, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, Japan.
AD  - Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, 
      Shinjuku-ku, Tokyo 151-0053, Japan.
FAU - Nakamura, Masaki
AU  - Nakamura M
AD  - Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, 
      Shinjuku-ku, Tokyo 151-0053, Japan.
AD  - Department of Somnology, Tokyo Medical University, 6-7-1, Nishishinjuku, 
      Shinjuku-ku, Tokyo 160-0023, Japan.
AD  - Aoyama-Omotesando Sleep Stress Clinic, Aoyama Rise Square 3F, 5-1-22 
      Minamiaoyama, Minato-ku, Tokyo 107-0062, Japan.
FAU - Hayashida, Kenichi
AU  - Hayashida K
AD  - Sleep Support Clinic, Miranbeena 1F, 1-18-8 Higashioi, Shinagawa-Ku, Tokyo 
      140-0011, Japan.
FAU - Takeuchi, Noboru
AU  - Takeuchi N
AD  - Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, 
      Shinjuku-ku, Tokyo 151-0053, Japan.
AD  - Department of Somnology, Tokyo Medical University, 6-7-1, Nishishinjuku, 
      Shinjuku-ku, Tokyo 160-0023, Japan.
AD  - Department of Neuropsychiatry, Kurume University School of Medicine, 67 
      Asahi-machi, Kurume 830-0011, Japan.
FAU - Inoue, Yuichi
AU  - Inoue Y
AUID- ORCID: 0000-0001-7414-9017
AD  - Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, 
      Shinjuku-ku, Tokyo 151-0053, Japan.
AD  - Department of Somnology, Tokyo Medical University, 6-7-1, Nishishinjuku, 
      Shinjuku-ku, Tokyo 160-0023, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220522
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Disorders of Excessive Somnolence/epidemiology
MH  - Humans
MH  - *Idiopathic Hypersomnia
MH  - Japan/epidemiology
MH  - *Metabolic Syndrome/epidemiology
MH  - *Narcolepsy/epidemiology
MH  - Obesity
PMC - PMC9141676
OTO - NOTNLM
OT  - HLA-DQB1*06:02
OT  - metabolic syndrome
OT  - narcolepsy spectrum disorders
OT  - narcolepsy type 2
OT  - obesity
OT  - orexin
COIS- Futenma reports personal fees from (1) Eisai Co., Ltd. and (2) MSD outside the 
      submitted work. Takaesu reports personal fees from (1) Eisai Co., Ltd., (2) MSD, 
      (3) Otsuka Pharmaceutical, (4) Dainippon Sumitomo Pharma and (5) Takeda 
      Pharmaceutical outside the submitted work. Nakamura reports personal fees from 
      (1) Eisai Co., Ltd., (2) MSD and (3) Ono Pharmaceutical outside the submitted 
      work. Hayashida reports personal fees from (1) Eisai Co., Ltd. and (2) MSD 
      outside the submitted work. Takeuchi reports no conflict of interest. Inoue 
      reports personal fees from (1) Eisai Co., Ltd., (2) Otsuka Pharmaceutical Co., 
      Ltd., (3) Takeda Pharmaceutical Co., Ltd., (4) Astellas Pharma Inc. and (5) MED 
      K.K. outside the submitted work and grants from (1) Philips Japan Co., Ltd., (2) 
      Koike Medical Co., Ltd. and (3) Teijin Pharma Ltd. outside the submitted work.
EDAT- 2022/05/29 06:00
MHDA- 2022/06/01 06:00
PMCR- 2022/05/22
CRDT- 2022/05/28 01:19
PHST- 2022/04/16 00:00 [received]
PHST- 2022/05/20 00:00 [revised]
PHST- 2022/05/21 00:00 [accepted]
PHST- 2022/05/28 01:19 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/22 00:00 [pmc-release]
AID - ijerph19106285 [pii]
AID - ijerph-19-06285 [pii]
AID - 10.3390/ijerph19106285 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2022 May 22;19(10):6285. doi: 
      10.3390/ijerph19106285.